Evidence map›Paper›PMID 29594385›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2018

Cripto-1 is overexpressed in carcinoma ex pleomorphic adenoma of salivary gland.

Leorik Pereira Silva, Luiz Arthur Barbosa da Silva, Bruno Tavares Sedassari, Suzana Cantanhede Orsini Machado de Sousa, Joabe Dos Santos Pereira, Lélia Batista de Souza, Márcia Cristina da Costa Miguel

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Leorik Pereira SilvaPostgraduate Program in Oral Pathology, Federal University of Rio Grande do Norte, Av. Sen Salgado Filho, 1787, Lagoa Nova, Natal, RN, 59056-000, Brazil. leorikp@gmail.com.
Luiz Arthur Barbosa da SilvaPostgraduate Program in Oral Pathology, Federal University of Rio Grande do Norte, Av. Sen Salgado Filho, 1787, Lagoa Nova, Natal, RN, 59056-000, Brazil.
Bruno Tavares SedassariDepartment of Oral Pathology, School of Dentistry, University of São Paulo, Av. Lineu Prestes, 2227, São Paulo, SP, Brazil.
Suzana Cantanhede Orsini Machado de SousaDepartment of Oral Pathology, School of Dentistry, University of São Paulo, Av. Lineu Prestes, 2227, São Paulo, SP, Brazil.
Joabe Dos Santos PereiraPostgraduate Program in Oral Pathology, Federal University of Rio Grande do Norte, Av. Sen Salgado Filho, 1787, Lagoa Nova, Natal, RN, 59056-000, Brazil.
Lélia Batista de SouzaPostgraduate Program in Oral Pathology, Federal University of Rio Grande do Norte, Av. Sen Salgado Filho, 1787, Lagoa Nova, Natal, RN, 59056-000, Brazil.
Márcia Cristina da Costa MiguelPostgraduate Program in Oral Pathology, Federal University of Rio Grande do Norte, Av. Sen Salgado Filho, 1787, Lagoa Nova, Natal, RN, 59056-000, Brazil.
Universidade Federal do Rio Grande do Norte · BRUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCripto-1 is a member of the epidermal growth factor-Cripto-1/FRL-1/Cryptic family. Besides being critical for early embryonic development, Cripto-1 is also associated with the development and behavior of several cancers.

objectiveWe analyzed the immunoexpression of Cripto-1 in normal salivary glands (NSGs), pleomorphic adenomas (PAs), and carcinoma ex pleomorphic adenomas (CaExPAs) of salivary glands.

methodsA total of 12 NSGs, 16 PAs and 12 CaExPAs underwent immunohistochemical study by the polymeric biotin-free technique. Immunopositive cells were evaluated semiquantitatively (scores 0-3). For statistical analysis, Mann-Whitney and Kruskal-Wallis tests were performed and a significance level of p ≤ 0.05 was established.

resultsMost CaExPAs (n = 10) were strong positive (score 3) for Cripto-1, and only three cases of PAs and two specimens of NSGs exhibited some expression (score 1), being statistically significant these findings (p < 0.001). No difference between the expression of this protein in tumors of major and minor salivary glands was observed. Overexpression was found mainly in cases of CaExPAs with invasive growth (n = 8) when compared to those without capsular invasion (intracapsular pattern) (p = 0.036). Patients with or without lymph node metastasis showed no difference (p = 0.294).

conclusionThe results revealed a significantly higher expression of Cripto-1 in CaExPA compared to PA and NSG, suggesting this protein is possibly deregulated in PA malignant transformation. Furthermore, the increased expression of this protein is associated with a more aggressive behavior (invasive growth) in salivary gland tumors.

Indexed as

AdenocarcinomaAdenoma, PleomorphicAdultAgedCase-Control StudiesFemaleGPI-Linked ProteinsHumansImmunohistochemistryIntercellular Signaling Peptides and ProteinsMaleMiddle AgedNeoplasm ProteinsSalivary Gland NeoplasmsSalivary Glands, MinorGPI-Linked ProteinsIntercellular Signaling Peptides and ProteinsNeoplasm ProteinsTDGF1 protein, humanImmunohistochemistryMalignant neoplasmSalivary gland

Identifiers

PMID29594385
OpenAlexW2795497522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.